Guided Therapeutics (GTHP) Long-Term Deferred Tax (2013 - 2025)

Guided Therapeutics (GTHP) has 6 years of Long-Term Deferred Tax data on file, last reported at $15.6 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Deferred Tax changed N/A year-over-year to $15.6 million; the trailing twelve-month figure through Dec 2025 stood at $15.6 million (changed N/A YoY), and the FY2025 full-year result was $15.6 million, changed N/A from the prior year.
• Long-Term Deferred Tax fell to $15.6 million in Q4 2025, from $16.4 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $17.1 million in Q4 2022 to a low of $15.6 million in Q4 2025.
• A 3-year average of $16.4 million and a median of $16.4 million in 2023 frame the typical range for Long-Term Deferred Tax.
• Peak annual rise in Long-Term Deferred Tax reached 3.91% in 2023, while the deepest fall reached 3.91% in 2023.
• Tracing GTHP's Long-Term Deferred Tax over 3 years: stood at $17.1 million in 2022, then declined by 3.91% to $16.4 million in 2023, then retreated by 4.82% to $15.6 million in 2025.
• Business Quant data shows GTHP's Long-Term Deferred Tax at $15.6 million in Q4 2025, $16.4 million in Q4 2023, and $17.1 million in Q4 2022.